The association between chronic inflammation and increased risk of cardiovascular disease
in rheumatoid arthritis (RA) is well established. In the general population, inflammation is an …

Despite major advances in prevention and treatment, cardiac and cerebral atherothrombotic
complications still account for substantial morbidity and mortality worldwide. In this context …

Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces
inflammation and cardiovascular event rates with no effect on lipid concentrations. However …

Accumulating observations in humans and animals indicate that inflammation plays a key
role in atherosclerosis development and subsequent complications. Moreover, the use of …

Following a myocardial infarction (MI), the immune system helps to repair ischaemic
damage and restore tissue integrity, but excessive inflammation has been implicated in …

The association between thrombosis and acute coronary syndromes is well established.
Inflammation and activation of innate and adaptive immunity are another important factor …

Introduction Persistent and excess IL-6 production often contributes to a variety of immune
diseases. IL-6–targeting therapy was first approved for Castleman disease, then rheumatoid …

Background Atherosclerosis is recognized as a systemic low‐grade inflammatory disease.
Furthermore, the dysregulation of the inflammatory response and its timely resolution is a …

Incidence and mortality rates for cardiovascular disease are declining, but it still remains a
major cause of morbidity and mortality. Drug treatments to slow the progression of …

Drug repurposing, also known as drug repositioning, entails the application of pre-approved
or formerly assessed drugs having potentially functional therapeutic amalgams for curing …